Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 3Peripheral Nervous System Diseases 3Ovarian Neoplasms 3Carcinoma, Hepatocellular 3Stomatitis 2Stomach Neoplasms 2Ototoxicity 2Neurofibromatosis 1 2Liver Neoplasms 2Hearing Loss 2Head and Neck Neoplasms 2Weight Loss 1Ulcer 1Tongue Neoplasms 1Tomaculous neuropathy 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Radiation-Induced Mucositis 1Radiation Pneumonitis 1Pseudomyxoma Peritonei 1Primary Myelofibrosis 1Primary Graft Dysfunction 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Osteosarcoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroma 1

Interventions

Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Ear Diseases × Acetylcysteine × Clear all
NCT04291209 2023-09-06

Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.

Sunnybrook Health Sciences Centre

Phase 1/2 Unknown
80 enrolled

Deafness, Ear Diseases, Hearing Loss, Sensorineural, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡